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Abstract
Introduction: Adenosine receptors (ARs), belonging to the G-protein-coupled receptors (GPCRs), are present in the majority of human 
cells and tissues. Depending on their biochemical and pharmacologic properties, four subtypes of ARs (i.e. A1, A2A, A2B, and A3) have been 
distinguished. Currently, these receptors are attractive molecular targets for pharmacological interventions in various diseases, including 
diabetes. The literature published to date has shown an altered expression of ARs in several types of cells under diabetic conditions. How-
ever, there has been no publication devoted to the investigation of ARs expression in leukocytes of subjects with gestational diabetes 
mellitus (GDM). Therefore, this study was aimed to determine the expression level of AR subtypes in leukocytes of GDM patients and its 
relationship to anthropometric and biochemical parameters.
Material and methods: Gene expression of four AR subtypes in leukocytes of both healthy (n = 34) and GDM (n = 67) subjects in the third 
trimester of pregnancy (from 24 to 33 weeks) was investigated. Multiple regression analyses were used to assess the association between 
the expression level of ARs and both anthropometric and biochemical parameters.
Results: Statistically significant (p < 0.05) higher levels of A2A and A2B mRNAs were observed in leukocytes of the GDM subjects compared 
to the control group. There was a positive correlation of A2B mRNA level with glucose concentration at 120 min of oral glucose tolerance 
test (OGTT) (r = 0.24, p = 0.041).
Conclusions: Overexpression of A2BAR in leukocytes of the GDM subjects and, additionally, the existence of a relationship between its 
elevated expression level in these cells and abnormal values of glucose concentration at 120 min of OGTT for GDM, suggest that this 
subtype might be involved in the pathogenesis of GDM. (Pol J Endocrinol 2012; 63 (2): 110–114)
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Streszczenie
Wstęp: Receptory adenozynowe (ARs) należą do błonowych receptorów sprzężonych z białkami G, które są obecne w większości ludz-
kich komórek i tkanek. Na podstawie ich biochemicznych i farmakologicznych właściwości wyróżniono cztery podtypy ARs (tj. A1, A2A, 
A2B, A3). Obecnie receptory te stanowią atrakcyjne molekularne cele dla farmakologicznych interwencji w różnych chorobach, w tym 
cukrzycy. W dostępnym piśmiennictwie istnieją dane wskazujące, że poziom ekspresji receptorów może ulegać zmianom w niektórych 
typach komórek podczas cukrzycy, natomiast nie ma publikacji dotyczących badania ekspresji ARs w leukocytach pacjentek z cukrzycą 
ciążową (GDM). Dlatego celem pracy było określenie poziomu ekspresji czterech podtypów ARs w leukocytach kobiet z GDN i ich korelacja 
z wybranymi parametrami antropometrycznymi i metabolicznymi.
Materiał i metody: Poziom ekspresji czterech podtypów ARs badano w leukocytach kobiet w ciąży, zarówno zdrowych (n = 34; grupa 
kontrolna), jak i ze zdiagnozowaną GDM (n = 67). Poziomy ekspresji korelowano z oznaczonymi parametrami antropometrycznymi 
i biochemicznymi.
Wyniki: W grupie GDM zaobserwowano istotny statystycznie (p < 0,05) wzrost poziomu mRNA receptorów A2A and A2B w porównaniu 
z grupą kontrolną. Zaznaczyła się również dodatnia korelacja między poziomem ekspresji receptora A2B a stężeniem glukozy w 2. godzinie 
testu doustnego obciążenia 75 g glukozy (r = 0,24; p = 0,041).
Wnioski: Zarówno istotnie podwyższony poziom ekspresji receptora A2B w leukocytach kobiet z GDM, jak i istnienie dodatniej korelacji 
między poziomem ekspresji receptora A2B w tych komórkach a stężeniem glukozy wskazują na jego potencjalny udział w patogenezie 
GDM. (Endokrynol Pol 2012; 63 (2): 110–114)
Słowa kluczowe: cukrzyca ciążowa, receptory adenozynowe, ekspresja genów
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Introduction
To date, four adenosine receptor (AR) subtypes, termed 
A1, A2A, A2B, and A3, have been cloned from various 
species and characterised structurally, functionally 
and pharmacologically. It is now well established that 
all subtypes of ARs are transmembrane glycoproteins 
belonging to the G-protein-coupled receptors (GP- 
-CRs) activated by adenosine [1–3]. Due to their wide 
distribution throughout the body, these receptors play 
an important role in many physiological and biochemi-
cal processes such as synaptic transmission, platelet 
aggregation, inflammation, glucose homeostasis and 
lipolysis [4, 5]. Moreover, ARs have been implicated 
in the pathogenesis of disorders such as cardiac and 
ischaemic diseases, asthma, chronic obstructive pulmo-
nary disease (COPD), Parkinson’s disease, retinopathy, 
cancer, obesity and diabetes [6–10]. With regard to the 
significance of ARs in type 2 diabetes mellitus (T2DM), 
considerable advances have been made towards ex-
plaining the role of the adipocyte A1AR in the inhibition 
of lipolysis, and consequently an increase of insulin 
sensitivity [11, 12]. For this purpose, many studies using 
adenosine analogues both as agonists and antagonists 
have been carried out in cell-based systems and/or 
animal models [10, 13, 14]. Interestingly, recent studies 
have suggested a potential role for other AR subtypes 
in diabetes [15–17], but the underlying mechanisms 
remain poorly understood. The pathogenesis of GDM 
is still unclear [18]. The role of insulin resistance and 
insulin secretion disturbances are established, although 
new abnormalities have been recently found [19–21].
Since metabolic abnormalities such as chronic insulin 
resistance and pancreatic b-cell dysfunction characterise 
both T2DM and GDM [22], GDM gives the opportunity 
to investigate the early pathogenesis of T2DM [18, 23]. 
On the other hand, despite extensive studies into the 
role of ARs in T2DM, there is lack of knowledge concern-
ing their role in GDM. Therefore, the aim of this study 
was to investigate the expression of the AR subtypes in 
leukocytes of GDM diagnosed women and (to correlate 
their expression level with anthropometric parameters 
i.e. body mass index [BMI] and body weight gain, as 
well as biochemical parameters, i.e. fasting: triglycerides 
[TGs], total cholesterol, high- and low-density lipopro-
tein HDL- and LDL-cholesterol), glycated haemoglobin 
(HbA1C), and glucose at 0, 60, and 120 min of oral glucose 
tolerance test (OGTT).
Material and methods
Participants
The study group consisted of 101 white pregnant wom-
en. 67 of them had been diagnosed with GDM according 
to WHO criteria [24]. They were aged 29.6 ± 4.7 years 
(mean ± SD). There were also 34 healthy controls, aged 
28.6 ± 4.2 years (mean ± SD), in the third trimester of 
pregnancy (24–33 weeks). All those participating in this 
study were recruited from the Polish Mothers’ Memorial 
Hospital Research Institute in Lodz, Poland. Approval 
for this study was obtained from the Ethical Commit-
tee of the Medical University of Lodz, and informed 
consent was obtained from all participating subjects.
Biochemical measurements
Blood samples were drawn after a 12 h overnight fast. 
Serum TGs, and HDL- and LDL-cholesterol levels were 
determined by enzymatic colorimetric methods using 
triglyceride GPO-PAP and Total Cholesterol CHOD-PAP 
kits (Roche Diagnostics, Mannheim, Germany). OGTT 
was carried out with 75 g standardised glucose solu-
tion. HbA1c was measured by immunoturbidimetry. 
Biochemical assays were carried out on a COBAS IN-
TEGRA analyser (Roche).
Gene expression assay
Leukocytes, isolated from blood (10 mL) of healthy and 
GDM pregnant women, were suspended in TriReagent 
(Sigma-Aldrich, St Louis, MO, USA). Then total mRNA 
from these cells was extracted according to the manu-
facturer’s instructions. The concentration of RNA and 
its purity were assessed by UV spectrophotometer 
LAMBDA 25 (PerkinElmer, UK) at UV260 and UV260/280, 
respectively. The first cDNA strand was synthesised 
with the use of total RNA (4 µg), in the presence of a (dT) 
primer and RevertAid™ H Minus M-MuLV reverse tran-
scriptase, according to the manufacturer’s instructions 
(Fermentas, Lithuania). The expression level of ARs 
was analysed by a semi-quantitative PCR performed 
in a Thermocycler TPersonal 48 (Biometra, Germany). 
Gene expression was normalised to the housekeeping 
gene GAPDH. The primers for PCR were designed based 
on the GenBank database sequences and are listed in 
Table I. Each PCR reaction was run in duplicate in a so-
lution containing 1 µL cDNA template, 1 µM primers 
(forward and reverse), 200 µM dNTPs, reaction buffer, 
and 0.6 U of Taq polymerase (Polgen, Poland), giving 
a final volume of 20 µL. The amplification products 
were analysed by 1.2% agarose gel electrophoresis and 
quantified by densitometry with the Gelix One 220 
programme (Biostep GmbH, Germany). The ratio of 
AR/GAPDH was calculated for each sample.
Statistical analysis
The statistical analysis was performed with Sta-
tistica 8.0 software (StatSoft, Poland, licence no 
AXAP911E504325AR-K). Comparison between the 
results of the control and GDM groups was made with 
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the Student t test. Pearson correlation analysis was used 
to quantify relationships between the expression level of 
A2A and A2B ARs and the value of each anthropometric 
and biochemical parameter. Values were considered to 
be statistically significant when p < 0.05. The results are 
given as mean ± SD.
Results
Anthropometric and biochemical characteristics
Table II summarises the anthropometric and clinical 
characteristics of the study groups. No significant differ-
ences were found between the groups of patients either 
in anthropometric parameters (age, BMI, body weight 
gain during pregnancy) or in serum total cholesterol, 
HDL- and LDL-cholesterol concentrations. Significantly 
higher levels of serum glucose at 0, 60, and 120 min of 
OGTT as well as TGs and HbA1c were found in GDM 
patients compared to healthy pregnant patients.
Expression levels of ARs mRNA
To evaluate the hypothesis of a possible role of ARs in 
the pathogenesis of GDM, we studied the gene expres-
sion of all four subtypes of ARs in blood leukocytes. We 
observed significantly higher levels of both A2A and 
A2B mRNA expression in leukocytes in the GDM group 
compared to the control group (A2AAR: 0.84 ± 0.41 
versus 0.55 ± 0.35, p = 0.001; A2BAR: 0.94 ± 0.5 versus 
0.64 ± 0.39, p = 0.003) as depicted in Figure 1A. In the 
cases of A1 and A3 ARs, there were no significant differ-
ences between the GDM group and the control group.
Next, we determined whether the expression levels 
of ARs were related to the anthropometric and biochem-
ical parameters depicted in Table II. Our results revealed 
the lack of a significant relationship of leukocyte A1, A2A 
and A3 mRNA expression with these parameters. A2BAR 
mRNA level correlated significantly only with the 
glucose concentration at 120 min of OGTT (r = 0.24, 
p = 0.041) (Figure 1B) in the whole examined group.
Table I. PCR primer sequences
Tabela I. Sekwencje starterów wykorzystywanych w PCR
Gene Primer sequence 5’ Æ 3’ Gene ID
Forward Reverse 
GAPDH CTGCACCACCAACTGCTTAG GTTGCTGTAGCCAAATTCGTTG NM_002046
A1AR AATCTGAGTGCGGTGGAGC CTCTTCTGGGAGATCCTCGTC EF057066
A2AAR TCACTTTCTTCTGCCCCGACTGC TGGCTAAGGAGCTCCACGTCTG NM_000675
A2BAR GACAGTGCCACCAACAACTGCAC CCAGCCTGACCATTCCCACTC NM_000676
A3AR TCAGAGTACCACAGAAATGTCAC CAGAATTCTTCTCAATGCTTGTGTC NM_000677
Table II. Anthropometric and clinical characteristics of control and GDM pregnant patients
Tabela II. Antropometryczna i kliniczna charakterystyka grupy kontrolnej i kobiet z GDM
Parameter Control patients (n = 34) GDM patients (n = 67) t test 
p value
Age (years) 28.6 ± 4.2 29.6 ± 4.7 0.307
BMI [kg/m2] 24.0 ± 3.8 24.9 ± 5.7 0.389
Body weight gain [kg] 9.5 ± 5.7 9.7 ± 5.9 0.905
Total cholesterol [mg/dL] 254.4 ± 42.1 268.3 ± 42.5 0.270
HDL-cholesterol [mg/dL] 80.3 ± 14.3 69.2 ± 23.1 0.055
LDL-cholesterol [mg/dL] 131.7 ± 40.8 146.0 ± 42.4 0.248
TGs [mg/dL] 219.2 ± 55.4 276.3 ± 80.0 0.007*
HbA1c (%) Glucose [mg/dL]: 5.2 ± 0.4 5.4 ± 0.4 0.002*
at 0 min of OGTT 77.1 ± 8.0 90.1 ± 20.3 < 0.001*
at 60 mins of OGTT 145.0 ± 33.1 190.9 ± 31.1 < 0.001*
at 120 mins of OGTT 114.0 ± 21.9 165.0 ± 21.9 < 0.001*
Results are given as mean ± SD; *significant differences between the means of two groups of patients (p < 0.05)
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Discussion
GDM, a common metabolic disorder occurring dur-
ing pregnancy, is defined as glucose intolerance that 
appears, or is first recognised, during pregnancy [25]. 
Metabolic abnormalities such as chronic insulin resis-
tance and pancreatic b-cell dysfunction characterise 
both GDM and T2DM, and therefore GDM provides 
an opportunity to investigate the early pathogenesis 
of T2DM [22]. Although the mechanisms that account 
for insulin resistance in both GDM and T2DM are 
not completely understood, the role of ARs in T2DM, 
particularly A1AR, has been identified. Indeed, A1AR 
expression is increased in diabetes, and additionally, its 
activation by adenosine analogues (i.e. agonists) results 
in suppression of lipolysis associated with the reduc-
tion of circulating free fatty acid (FFA) levels [10, 13]. 
Recent studies have reported that the expression level 
of all ARs subtypes is changed in the liver, heart, and T 
lymphocytes of diabetic rats, suggesting a potential role 
in the pathogenesis of diabetes and its complications 
[15–17, 26, 27]. Moreover, the involvement of A2BAR in 
diabetes was supported by a study with the use of A2B 
receptor antagonist, 2-alkynyl-8-aryl-9-methyladenine, 
which suppressed glucose production from rat hepa-
tocytes and had hypoglycaemic activity in a diabetic 
rat model [28].
Given that ARs represent attractive molecular targets 
for the development of drugs that might be used for the 
treatment of insulin resistance, metabolic syndrome, and 
T2DM, our particular interest was to determine whether 
the adenosine receptors mRNA levels are altered in the 
leukocytes of GDM women. It should be noted that 
although the distribution of ARs has been extensively 
studied, revealing the presence of all four types of these 
receptors on the various immune cell types [29], there 
is lack of knowledge about their expression levels in 
leukocytes of GDM patients. In this study, we show that 
leukocytes obtained from women with GDM are charac-
terized by a significant increase (p < 0.05) in the A2A and 
A2B expression levels. Moreover, a positive correlation 
between the expression level of A2B ARs in these cells and 
abnormal values of glucose concentration at 120 min of 
75 g OGTT for GDM was found. This association is not 
surprising in the context of data showing that changes in 
the expression levels of ARs in diabetic T cells may result 
from hyperglycaemia and/or hypoinsulinaemia [26]. On 
the other hand, we cannot exclude the possibility that 
changes in the levels of hormones and/or oxidative stress 
during GDM might affect the A2A AR and A2BAR mRNA 
expression [30]. Therefore, the establishment of both the 
causes, and the functional consequences, of the altered 
expression of ARs should represent an exciting goal for 
further studies.
Conclusions
Our study demonstrates for the first time significantly 
higher expression levels of two subtypes of ARs, i.e. A2A 
and A2B ARs, in leukocytes of GDM subjects compared 
to healthy pregnant women; in addition, we demon-
strated a positive correlation between the expression 
of A2BAR and the glucose level at 120 min of OGTT. 
Therefore, A2BAR seems to play an important role in 
glucose metabolism during GDM. However, whether 
these findings will be confirmed in larger studies with 
a broader representation among women with GDM 
remains to be determined.
Figure 1. A. Expression levels of four subtypes of ARs normalised to GAPDH mRNA in leukocytes of GDM patients. 
Control group (n = 34, white columns), GDM women (n = 67, grey columns); B. Positive correlation between A2B 
expression level and a 2-h 75-g OGTT (r = 0.24, p = 0.041); *significant differences (p < 0.05)
Rycina 1. A. Poziomy ekspresji czterech podtypów receptorów adenozynowych normalizowane do GAPDH w leukocytach 
kobiet z GDM. Grupa kontrolna (n = 34, białe kolumny), kobiety z GDM (n = 67, szare kolumny); B. Pozytywna korelacja 
między poziomem ekspresji receptora A2B a stężeniem glukozy w 2. godzinie testu OGTT (r = 0,24; p = 0,041); *różnice 
istotne statystycznie (p < 0,05)
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